Cargando…

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease

Cerebrospinal fluid (CSF) biomarkers based on the core pathological proteins associated with Alzheimer’s disease (AD), i.e., amyloid-β (Aβ) and tau protein, are widely regarded as useful diagnostic biomarkers. However, a lack of biomarkers for monitoring the treatment response and indexing clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Sun Ah, Han, Song Mi, Kim, Chae Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210893/ https://www.ncbi.nlm.nih.gov/pubmed/32284537 http://dx.doi.org/10.1038/s12276-020-0418-9

Ejemplares similares

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
por: Lee, Jinny Claire, et al.
Publicado: (2019)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
por: Turk, Katherine W., et al.
Publicado: (2022)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology
por: Solas, Maite, et al.
Publicado: (2023)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Brainstem tau pathology in Alzheimer’s disease is characterized by increase of three repeat tau and independent of amyloid β
por: Uematsu, Miho, et al.
Publicado: (2018)

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
por: Koychev, Ivan, et al.
Publicado: (2017)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Novel Alzheimer risk genes determine the microglia response to amyloid‐β but not to TAU pathology
por: Sierksma, Annerieke, et al.
Publicado: (2020)

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
por: Bellaver, Bruna, et al.
Publicado: (2023)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease
por: Pascoal, Tharick, et al.
Publicado: (2023)

Convergence of Amyloid-β and Tau Pathologies on Mitochondria In Vivo
por: Eckert, Anne, et al.
Publicado: (2010)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Disease-Modifying Effects of Non-Invasive Electroceuticals on β-Amyloid Plaques and Tau Tangles for Alzheimer’s Disease
por: Bok, Junsoo, et al.
Publicado: (2022)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis
por: Hirota, Yu, et al.
Publicado: (2022)

Amyloid β and Tau Alzheimer’s disease related pathology is reduced by Toll-like receptor 9 stimulation
por: Scholtzova, Henrieta, et al.
Publicado: (2014)

Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology
por: Kehoe, Patrick Gavin, et al.
Publicado: (2016)

Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies
por: Guedes, Joana R., et al.
Publicado: (2018)

Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer’s disease
por: Frigerio, Irene, et al.
Publicado: (2021)

Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer’s disease
por: Guzmán-Vélez, Edmarie, et al.
Publicado: (2022)

Correction: Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K., et al.
Publicado: (2018)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers
por: Spotorno, Nicola, et al.
Publicado: (2022)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease
por: Shim, Kyu Hwan, et al.
Publicado: (2022)

Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium
por: Xie, Zhongcong, et al.
Publicado: (2014)

NLRP3 Inflammasome: A Starring Role in Amyloid-β- and Tau-Driven Pathological Events in Alzheimer’s Disease
por: Van Zeller, Mariana, et al.
Publicado: (2021)

The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer's Disease Biomarkers
por: Shin, Ho Sik, et al.
Publicado: (2016)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease
por: Ower, Alison K., et al.
Publicado: (2017)

Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease
por: Gerrits, Emma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_90j8t5us7oq811nltg18gi90d9